Imara presents clinical data on imr-687 in sickle cell disease at the european hematology association (eha) annual congress

Final data from 93-patient phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (vocs) and longer time to first voc on imr-687

ELVN Ratings Summary

ELVN Quant Ranking